

A potential robust antiviral defense state in the common vampire bat: Expression, induction and molecular characterization of the three interferon-stimulated genes -OAS1, ADAR1 and PKR

Sarkis Sarkis, Stéphanie Dabo, Marie-Claude Lise, Christine Neuveut, Eliane Meurs, Vincent Lacoste, Anne Lavergne

▶ To cite this version:

Sarkis Sarkis, Stéphanie Dabo, Marie-Claude Lise, Christine Neuveut, Eliane Meurs, et al.. A potential robust antiviral defense state in the common vampire bat: Expression, induction and molecular characterization of the three interferon-stimulated genes -OAS1, ADAR1 and PKR. Developmental and Comparative Immunology, 2018, 85, pp.95-107. 10.1016/J.DCI.2018.04.006 . pasteur-02197397

HAL Id: pasteur-02197397 https://riip.hal.science/pasteur-02197397

Submitted on 6 Apr 2020 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	A potential robust antiviral defense state in the common vampire bat: expression,
2	induction and molecular characterization of the three interferon-stimulated genes -
3	OAS1, ADAR1 and PKR
4	
5	Sarkis Sarkis ^{a,*} , Stéphanie Dabo ^b , Marie-Claude Lise ^a , Christine Neuveut ^b , Eliane F.
6	Meurs ^b , Vincent Lacoste ^a and Anne Lavergne ^{a, *}
7	
8	^a Laboratoire des Interactions Virus-Hôtes, Institut Pasteur de la Guyane, Cayenne, French
9	Guiana
10	
11	^b Hepacivirus and Innate Immunity, Institut Pasteur, 75015 Paris, France
12	
13	* Corresponding authors.
14	Laboratoire des Interactions Virus-Hôtes, Institut Pasteur de la Guyane, 23 avenue Pasteur,
15	97300 Cayenne, French Guiana.
16	E-mail adresses : <u>sarkis.sarkis@hotmail.com</u> (S. Sarkis); <u>alavergne@pasteur-cayenne.fr</u> (A.
17	Lavergne)
18	
19	Keywords: Desmodus rotundus, Innate immunity, ISGs, OAS1a, OAS1b, ADAR1, PKR

21 Abstract

Bats are known to harbor many zoonotic viruses, some of which are pathogenic to other 22 mammals while they seem to be harmless in bats. As the interferon (IFN) response represents 23 the first line of defense against viral infections in mammals, it is hypothesized that activation 24 25 of the IFN system is one of the mechanisms enabling bats to co-exist with viruses. We have previously reported induction of type I IFN in a cell line from the common vampire bat, 26 *Desmodus rotundus*, upon polyinosinic:polycytidylic acid (poly(I:C)) stimulation. To deepen 27 28 our knowledge on D. rotundus' IFN-I antiviral response, we molecularly characterized three interferon-stimulated genes (ISGs), OAS1, PKR and ADAR1, closely implicated in the IFN-I 29 antiviral response, and tested their functionality in our cellular model. We first found that D. 30 rotundus encoded two OAS1 paralogs, OAS1a and OAS1b, and that the functional domains of 31 the four ISGs characterized were highly conserved with those of other mammals. Despite 32 their significant transcription level in the absence of stimulation, the transcription of the four 33 ISGs characterized was enhanced by poly(I:C). In addition, the transcription of OAS1a and 34 OAS1b appears to be differentially regulated. These findings demonstrate an active ISG 35 36 antiviral response in *D. rotundus* in which OAS1b may play an important role.

37

38 Highlights

Four ISGs implicated in the antiviral response were molecularly characterized.
Two *OAS1* paralogs were characterized in *D. rotundus*.
The functional domains of the characterized ISGs are highly conserved relative to their mammalian homologs.
Significant induction of Oas1b was observed after stimulation with poly(I:C).

45 **1. Introduction**

The interferon (IFN)-mediated innate immune response provides a robust first line of defense 46 against invading pathogens. Pathogen-associated molecular patterns' (PAMP) recognition by 47 pattern recognition receptors (PRRs) leads to a subsequent production of IFN, especially of 48 types I (IFN α/β) and III (IL28A, IL28B, IL29), considered as the main antiviral IFNs (Borden 49 50 et al., 2007). Newly synthesized IFN molecules up-regulate the transcription of hundreds of interferon-stimulated genes (ISGs) resulting in the production of various antiviral effectors 51 (Der et al., 1998). This cascade leads to a remarkable antiviral state of infected and 52 neighboring cells and limits the spread of infectious agents. Considering the large number of 53 ISGs activated upon IFN signaling, considerable redundancy in the system is likely. Among 54 the molecules with important biological functions induced by IFN are the 2'5' oligoadenylate 55 synthetase/ribonuclease L (OAS/RNase L) system, the adenosine deaminase RNA-specific 56 (ADAR) as well as the dsRNA-activated protein kinase (PKR), which play a critical role in 57 the host's antiviral defense mechanism and are among the most extensively studied ISGs (Der 58 et al., 1998; George and Samuel, 1999; Levy et al., 2002; Sen, 2001). Even though the 59 specific functions of mammalian OAS1, ADAR and PKR have yet to be clarified, their 60 structural (architectural) domain organizations are well characterized and show a high degree 61 of similarity among species. 62

The *OAS* gene family comprises three classes of genes in human, *OAS1*, *OAS2* and *OAS3*, in addition to an "*OAS-like*" (*OASL*), which is catalytically inactive. The mouse *OAS* cluster, the second most well known after the human *OAS* cluster, contains one *OAS2* and one *OAS3* gene; two *OASLs*, of which one is a pseudogene; and eight paralogs of *OAS1*, *Oas1a–Oas1h* (Kristiansen et al., 2011). Activation of the OAS proteins in presence of single-stranded (ss) or double-stranded (ds) RNA triggers the synthesis of 2'5' oligoadenylates. These in turn bind to and activate the latent RNaseL, which restricts viral propagation through direct and indirect

mechanisms, including i) viral genome degradation (RNA and DNA), ii) cellular mRNA 70 degradation, including mitochondrial RNA followed by apoptosis, as well as iii) amplification 71 of IFN signaling through the release of additional PAMPs activating cytoplasmic helicases, 72 which in turn activate type I IFN synthesis and create a positive feedback loop (Justesen et al., 73 2000; Malathi et al., 2007, 2005; Silverman, 2003; Xiang et al., 2003). Regarding its domain 74 organization, on its N-terminus OAS1 comprises a nucleotidyl transferase domain (NTP-75 transf 2) constituted of a dsRNA-binding domain flanked by two ATP-binding domains, 76 77 which plays a critical role in OAS1 activation. On its C-terminus, OAS1 presents the OAS1_C domain including the region of enzymatic activity thought to activate latent 78 RNAseL (Sarkar et al., 2002). 79

ADAR belongs to a family of proteins that modulate nucleic acid integrity and play an 80 81 important role in the defense against viral RNAs. All ADAR family members present doublestranded RNA-binding domains (dsRBDs) at their N-termini and a catalytic deaminase 82 domain located at their C-termini (Mannion et al., 2015). A unique feature of ADAR1, when 83 compared to other members of the ADAR family, is the presence of Z-DNA-binding domains 84 (ZBDs) at its N-terminus with a Z α and a Z β domain (Kim et al., 1999). In addition to the 85 86 capacity of the Zα domain to bind to Z-DNA/RNA (Herbert et al., 1997), it has been reported that all proteins containing this domain are implicated in the type I IFN response pathway 87 88 (Athanasiadis et al., 2005). Furthermore, the $Z\alpha$ domain is essential for the location of 89 ADAR1 to cytoplasmic stress granules following activation. Upon binding to dsRNA, ADAR1 induces editing of adenosine to inosine, one of the most abundant modifications of 90 mammalian RNA (Bazak et al., 2014; Goodman et al., 2012). However, depending on the 91 92 viral species, the editing event can make ADAR1 act as either a proviral or an antiviral factor. Indeed, whereas editing by ADAR1 of lymphocytic choriomeningitis virus introduces 93 mutations in viral proteins and reduces infectivity, editing of HIV-1 rev and tat proteins leads 94

to increased infectivity (Doria et al., 2009). In addition, ADAR1 can also exert a proviral
function through its Z-DNA and dsRBD domains by interacting with PKR, another dsRBDcontaining protein. Such interaction negatively regulates the antiviral function of PKR
(Clerzius et al., 2009).

PKR (protein kinase dsRNA-dependent) is one of the four eIF-2 α serine-threonine kinases 99 that controls protein synthesis through the phosphorylation of the alpha subunit of eukaryotic 100 initiation factor 2 (eIF-2a). PKR is ubiquitously expressed and can be induced upon IFN 101 treatment (Meurs et al., 1990, 1992; Williams, 2001). PKR becomes activated upon binding to 102 103 dsRNA, as during viral infection, or to cellular activators in response to stress (Dabo and Meurs, 2012). Because of PKR's role in controlling protein synthesis, it can inhibit infection 104 by a number of viruses. Nevertheless, other viruses, such as the hepatitis C virus, benefit from 105 106 the general shut-down of protein synthesis, which promotes their own eIF-2α-independent translation (Arnaud et al., 2010; Garaigorta and Chisari, 2009). In addition, PKR modulates 107 signaling pathways involved in inflammation independently of its enzymatic activity (Bonnet 108 et al., 2006; García et al., 2007). PKR consists of two functionally distinct domains: a N-109 terminal dsRNA binding regulatory domain (dsRBD) and a C-terminal kinase catalytic 110 domain. The dsRNA-binding domain contains two dsRNA-binding motifs (dsRBMs). These 111 motifs are rich in basic residues and confer to PKR the capability of binding to dsRNA 112 independently of the sequence. As a member of the kinase proteins, PKR presents all the 113 conserved catalytic kinase subdomains. In addition, the homology within subdomain VI 114 identifies PKR as a serine/threonine kinase (Meurs et al., 1990). PKR also possesses an insert 115 region C-terminal of Domain IV. This insert region and the dsRBD are key determinants of 116 117 the PKR function and regulation.

Bats are known to harbor many zoonotic viruses, some of which are pathogenic to other mammals while they seem to be harmless or only rarely associated with clinical signs in bats

(Moratelli and Calisher, 2015). Strikingly, mechanisms that allow bats to coexist with these 120 viruses have not yet been fully researched. It is currently acknowledged that early control of 121 viral replication by their innate immune system might be one of the mechanisms implicated, 122 enabling bats to coexist with viruses (Baker et al., 2013). Following the establishment of a 123 Desmodus rotundus cell line, FluDero, and the molecular characterization of the RIG-I-like 124 receptor members and of type I interferons (Sarkis et al., 2018), we studied several ISGs from 125 this bat species given that they are responsible for the antiviral activity of IFNs in mammals 126 (Der et al., 1998; He et al., 2014; Levy et al., 2002; Sen, 2001; Zhou et al., 2013). Here, we 127 describe the molecular characterization of three ISGs, OAS1, ADAR1 and PKR, from 128 Desmodus rotundus and report differential expression profiles for these genes upon 129 stimulation of the FLuDero fetal lung cell line with the synthetic analog of dsRNA, the 130 polyinosinic:polycytidylic acid, poly(I:C). 131

132 2. Materials and Methods

133 2.1. Cell line, cell culture and poly(I:C) stimulation

Establishment of the FluDero cell line has been described previously (Sarkis et al., 2018). 134 The cell line was cultured in prewarmed DMEM/Ham's Nutrient Mixture F12 (Sigma) 135 supplemented with 10% fetal bovine serum (FBS) (Sigma), 100 units/mL penicillin and 100 136 µg/mL streptomycin and was maintained in a humidified incubator with 5% CO₂ at 37°C. For 137 poly(I:C) stimulation, FLuDero cells were seeded at a density of 2.5×10^5 cells/well in 12-well 138 plates. Cells were stimulated by transfection with 20 µg/mL of poly(I:C) (Sigma, cat #P9582) 139 by calcium phosphate transfection (Invitrogen), 20 h after seeding. Cells were harvested in 140 TRIzol Reagent at 0, 3, 6, 9, 12, 24, 48 and 72 h post-transfection and stored at -80°C until 141 RNA extraction. The experiment was performed three times. 142

143 2.2. RNA extraction and cDNA synthesis

Total RNA was extracted from FLuDero cells transfected with poly(I:C) using TRIzol Reagent (Invitrogen) as recommended by the manufacturer. cDNAs were synthesized using Superscript[®]III reverse transcriptase (Invitrogen) and random hexamers following the manufacturer's instructions.

148 2.3. Sequence identification and domain characterization of OAS1, ADAR1 and PKR

To generate the full-length coding sequences of OAS1, ADAR1 and PKR, all 149 amplifications were performed on cDNA obtained from poly(I:C)-transfected FluDero cells. 150 Internal coding regions were amplified by PCR using the AmpliTag Gold DNA polymerase 151 kit (Thermo Fischer Scientific). Different combinations of consensus and specific degenerate 152 primers were designed using Primer3 (v.0.4.0) based on alignments of orthologous mammal 153 sequences, which were available in the GenBank database (Supplementary Table 1). The 5'-154 and 3'-terminal sequences were obtained by rapid amplification of cDNA ends (RACE) using 155 the FirstChoice[®] RLM-RACE Kit (Ambion, Inc.). PCR and RACE products were cloned 156 using the pCRTM4-TOPO[®] TA CLONING[®] KIT (Invitrogen). The sequences obtained were 157 the confirmed by similarity analysis using NCBI BLAST search tool 158 (http://www.ncbi.nlm.nih.gov/BLAST). The structural domains of each protein were 159 identified using SMART software (http://smart.embl-heidelberg.de/) (Letunic et al., 2015). 160 Multi-alignment was performed with the ClustalW program (https://npsa-prabi.ibcp.fr/cgi-161 <u>bin/npsa_automat.pl?page=/NPSA/npsa_clustalw.html</u>) using default parameters. 162

163 *2.4. Phylogenetic analysis*

164 The complete coding sequences for *ADAR1* and *PKR* of 18 and 17 representatives 165 Laurasiatherian and Euarchontoglires, respectively, were downloaded from the NCBI 166 database. Available sequences included those from the bat species *Eptesicus fuscus*, 167 *Miniopterus natalensis*, *Myotis brandtii*, *Myotis davidii*, *Myotis lucifugus*, *Pteropus alecto*,

Pteropus vampyrus, Rhinolophus sinicus and Rousettus aegyptiacus (Supplementary Table 168 2). The ISG sequences of *D. rotundus* obtained in this study were further added to each data 169 set. After alignment and editing, the MEGA version 6.0 software (Tamura et al., 2013) was 170 used to compute pairwise comparisons in the nucleotide and amino acid using uncorrected p-171 distances. The best-fit amino acid evolutionary substitution model (Jones-Taylor-Thornton + 172 G + F) was determined using MEGA version 6.0. Bayesian phylogenetic analyses were 173 performed using MrBAYES 3. Markov Chain Monte Carlo (MCMC) simulations were run 174 175 for 10,000,000 generations, with four simultaneous chains, using a sample frequency of 500 and a burn-in of 25,000. Majority rule consensus trees were obtained from the output. 176 Validation of the inference was assessed based on the standard deviation of split frequencies, 177 which was less than the expected threshold value of 0.01 (calculated value of 0.002). ADAR1 178 and PKR trees were rooted with the rodent Mus musculus sequences. Coding sequences from 179 33 representative mammalian species retrieved in NCBI were used for OAS1 pairwise 180 comparisons and phylogenetic analysis (Supplementary Table 2). Eight corresponded to the 181 bat species E. fuscus (two paralogs), M. natalensis (two paralogs), M. brandtii (two paralogs), 182 M. davidii, M. lucifugus (two paralogs), P. alecto, P. vampyrus and R. aegyptiacus. An OAS1 183 tree was constructed based on the alignment of amino acid residues and was rooted with 184 OASL sequences from M. natalensis, P. alecto, P. vampyrus and R. aegyptiacus. 185

186 2.5. Quantitative PCR

Quantitative PCR (qPCR) was performed on a StepOne[™] Real-Time PCR System using the TaqMan® Universal PCR Master Mix (Applied Biosystems). Primers and TaqMan® probes were designed using Primer Express 3.0 (Applied Biosystems) (**Supplementary Table 1**). Each reaction was performed in duplicate. The cycling conditions were those recommended by the manufacturer: 55°C for 2 min, 95°C for 2 min followed by 40 cycles at 95°C for 15 s, 60°C for 1 min. For absolute quantification, the exact number of copies of the 193 gene of interest was calculated using a plasmid DNA standard curve. Individual expression 194 values were normalized and compared to mRNA encoding β -actin. Values are shown 195 graphically as fold induction compared to the mock sample (0 h transfection) for each 196 experiment.

197 **3. Results**

198 3.1. Sequence characterization of D. rotundus OAS1a, OAS1b, ADAR1 and PKR genes

Primers derived from alignments of the orthologous mammalian OAS1, ADAR1 and PKR 199 200 sequences were used to characterize OAS1, ADAR1 and PKR genes from mRNA extracted from the FluDero cell line. The full-length coding sequences for ADAR1 and PKR were 201 202 identified. Sequence analysis revealed that their coding regions were 3444 and 1611 base 203 pairs (bp) long, respectively, encoding proteins of 1149 and 537 amino acids (aa), respectively. In addition, we characterized two OAS1 paralog genes in D. rotundus, which we 204 named OAS1a and OAS1b. The partial coding sequence of OAS1a was 1056 bp in length (352 205 206 aa). On the other hand, the complete coding region of OAS1b was 1101 bp long encoding a 367-aa protein. When comparing the OAS1a and OAS1b with their mammalian counterparts, 207 OAS1a seems to lack 17aa at its C-terminal. 208

Pairwise comparison done on 897 nucleotides corresponding to 299 amino acid residues 209 210 showed that the two OAS1 paralogs shared 81.6 and 77.3% of sequence identity at the nucleotide and amino acid levels, respectively. However, when compared to their mammalian 211 212 homologs, OAS1a showed a higher level of sequence identity at the nucleotide and amino acid levels than OAS1b. For instance, OAS1a exhibited 84% and 80% identity at the nucleotide 213 and amino acid levels, respectively, and OAS1b shared 78 and 73% identity with the OAS1 214 sequence of the Pteropus species. In the same way, OAS1a shared 73-80% amino acid 215 identity with its equine, canine, bovine and human homologs, while OAS1b presented 69-216

75% sequence identity (Supplementary Table 3). D. rotundus' ADAR1 and PKR were also 217 subjected to pairwise comparison with their mammalian homologs. Among the four ISGs 218 characterized, the complete amino acid sequence of ADAR1 displayed the highest level of 219 sequence identity with its mammalian counterparts, while PKR shared the lowest. For 220 instance, ADAR1 and PKR displayed 85.4-89.6% and 64.7-71% sequence identity at the 221 protein level with their bat homologs, respectively (Supplementary Table 3). In addition, 222 when comparing *D. rotundus PKR* with other mammalian homologs the identity at the protein 223 224 level was slightly lower.

225 3.2. Conserved domain organization in D. rotundus ISGs

One of the hallmarks of the ISGs is their domain architecture responsible for their 226 function. Sequence analysis of the two OAS1 paralogs identified in D. rotundus using the 227 SMART software showed that these two proteins presented a similar structural domain 228 229 organization to that described in their mammalian homologs. They possess the two characteristic functional domains of OAS1, *i.e.*, the NTP-transf 2 domain on their N-termini 230 and C-terminal OAS1 C domain. These domains are located between aa 36-121 and 162-231 345, respectively (all values are given relative to *H. sapiens* sequences) (Figure 1). The *D*. 232 rotundus OAS1a and OAS1b putative proteins showed conservation of the hallmark motifs 233 crucial for OAS1 activity, *i.e.*, the LxxxP sequence required for enzymatic activity, a P-Loop 234 motif with a (G[G/S]xx) sequence, which precedes the first triad residue corresponding to the 235 second signature of the nucleotidyl transferase superfamily formed by Asparagine residues 236 (represented with an inverted triangle), a K-R rich region and a CFK motif located in the C-237 terminal domain (Figure 1). Similarly, the D. rotundus ADAR1 protein contained all domains 238 necessary for its function, including at its N-terminus the two Za domains, a central dsRBD 239 with three dsRBM, and a catalytic deaminase domain at its C-terminus. These domains and 240 motifs are located between aa 132-202, 291-360, 504-569, 615-680, 727-793 and 840-241

1222, respectively (Figure 2a). Finally, the deduced protein sequence of D. rotundus PKR 242 showed the conservation of all domains relative to its function including the N-terminus 243 dsRBD with the two dsRBM (dsRBM1 and dsRBM2) between aa 9-81 and 102-169 (yellow 244 and light gray boxes, respectively) and all subdomains (open boxes) in the catalytic region. A 245 variable region was also found in D. rotundus PKR between the dsRBM2 and the basic region 246 (in dark gray) between aa 229 and 251. In addition, D. rotundus PKR presented a conserved 247 insert region at the C-terminal of subdomain IV (blue) between aa 362 and 370. However, D. 248 249 rotundus PKR did not possess the repeat sequence (green) found in the catalytic region of the human PKR, a common feature observed in other bat species and mice (Figure 2b). 250

251 3.3. The D. rotundus-characterized ISGs are closely related to their mammalian counterparts

To elucidate the evolutionary relationships of OAS1a and OAS1b, ADAR1 and PKR, 252 phylogenetic trees were constructed based on multiple amino acid alignments constructed 253 254 with other published mammal sequences (Figure 3). The OAS1 phylogenetic topology obtained was in agreement with the different mammalian orders, showing that OAS1a and 255 OAS1b from *D. rotundus* belonged to a single clade of chiropters. Within this clade, OAS1a 256 257 and OAS1b clustered with OAS1-like and OAS1 of microbats, respectively, and were supported with high posterior probability values (Figure 3a). On the other hand, the 258 phylogenetic analyses of ADAR1 (Figure 3b) and PKR (Figure 3c) showed that all bat 259 sequences belonged to a clade distinct from other mammal species, with the microbats (D. 260 rotundus, M. natalensis, E. fuscus and Myotis species) diverging from the megabats (Pteropus 261 262 species, *R. aegyptiacus*, and *R. sinicus*).

263 3.4. D. rotundus OAS1, ADAR1 and PKR can be induced in response to poly(I:C) stimulation

To investigate the functionality of these ISGs in FLuDero, we studied their expression profile after poly(I:C) transfection (**Figure 4**). The kinetics of the expression of OAS1a, OAS1b, ADAR1 and PKR mRNA revealed a similar induction profile. The induction was observed 6 h post-transfection, reaching a peak at 24 h followed by a decline at 48 h. Among the ISGs studied, *OAS1b* was the most inducible gene (400-fold up-regulation at 24 h) at all time points of the kinetics. In contrast, *ADAR1* and *PKR* were the least induced genes, showing a peak of induction at 24 h with a 15- and nine-fold induction, respectively. Strikingly, in the absence of stimulation, transcription of the four ISGs characterized was already significant, with a strong expression of PKR mRNA (**Figure 5,** 0 hrs).

274 **4. Discussion**

Viral infection in mammals often triggers the IFN-I-mediated frontline host defense 275 mechanism, leading to the transcription of a wide range of ISGs (Randall and Goodbourn 276 277 2008). These ISGs confer an antiviral state to the host and neighboring cells by several mechanisms, including inhibition of viral transcription, translation and replication, as well as 278 degradation of viral nucleic acids. We previously demonstrated that FLuDero cells were 279 competent to mount high levels of IFN-I after transfection with poly(I:C) (Sarkis et al., 2018). 280 To deepen our understanding of the D. rotundus' IFN-I antiviral response, we molecularly 281 characterized three ISGs, OAS1, PKR and ADAR1, closely implicated in the IFN-I antiviral 282 response and looked at their expression upon poly(I:C) stimulation of FLuDero cells. 283

Contrary to other mammals such as in human, which only possesses one OAS1 gene, we 284 characterized two OAS1 paralogs (OAS1a and OAS1b) in D. rotundus, a feature shared with 285 some bat species such as Myotis lucifigus, M. natalensis and E. fuscus, and other mammals 286 such as the mouse, which has several OAS1 paralogs. Nevertheless, even if the mouse 287 expresses eight OAS1 genes, only two (OAS1a and OAS1g) conserve their activities 288 (Elkhateeb et al., 2016). The other paralogs are non-functional due to mutations or deletions 289 of at least one of their functional domains. Multiple sequence alignment of D. rotundus 290 291 OAS1a and OAS1b with their mammalian ortholog sequences demonstrated that they have the same structural organization and are thus likely to possess similar enzymatic and antiviral 292 activities. For instance, the P-Loop motif, which is an ATP-binding site (Saraste et al., 1990; 293 Tag-El-Din-Hassan et al., 2012), the DAD motif in D box, which is a Mg²⁺-binding site 294 (Sarkar et al., 2002; Yamamoto et al., 2000), the KR-rich region, which is an oligoadenvlate 295 and ATP-binding site (Marié et al., 1997), and the CFK motif located in the C-terminal 296 domain, required for the tetramerization of the proteins, are all conserved (Ghosh et al., 1997). 297 298 In a previous study on P. alecto, Zhou and colleagues characterized a single OAS1 gene.

However, they did not exclude the possible existence of additional OAS1 paralogs given that 299 their analysis was based on a *P. alecto* genome assembly not fully achieved at the time of the 300 study (Zhou et al., 2013). In the database, many bat OAS1 genes have been annotated as 301 "OAS1-like" such as in M. lucifigus, P. vampyrus, M. natalensis and E. fuscus. However, 302 these genes do not show any mutation on their functional sites, which could result in a loss of 303 function (Guénet et al. 2015). Moreover, the OAS1 phylogenetic tree reveals that some bat 304 OAS1 and OAS1-like sequences are intermixed within different clades (Fig. 3a). A consensus 305 on "OAS1" naming is therefore needed. In this regard, the generation of more OAS1 306 sequences from other bat species should extend our understanding of their evolutionary 307 history. 308

The molecular characterization and domain prediction of PKR show that the regulatory 309 310 and kinase subdomains of the D. rotundus' PKR protein are remarkably conserved with respect to those of other mammals. For instance, the N-terminal domain of D. rotundus' PKR 311 includes a repeated motif (dsRBD) that possesses dsRNA-binding activity and the C-terminal 312 half of PKR includes the 11 conserved catalytic subdomains characteristic of kinases. Our 313 multiple sequence alignment of mammals' PKR shows the conservation of the major residues 314 crucial to the function of the protein such as the highly conserved lysine K⁶⁴ of the RNA-315 binding domain required for its RNA-binding activity, the K²⁹⁶ in the catalytic subdomain II 316 required for its kinase activity and the T⁴⁴⁶ within the activation loop that confers to PKR its 317 specificity as a serine/threonine kinase (Dabo and Meurs, 2012). In addition, the salt bridge 318 interaction of R^{262} and D^{266} at the dimer interface of PKR, which is critical to eIF2 α 319 phosphorylation and PKR activation, is also conserved (Dey et al., 2007). 320

Similarly, depending on the sequence alignment, ADAR1 is also highly conserved with those of other mammals. For instance, we found that residues H^{910} and E^{912} of the CHAE motif, considered as a key element of the catalytic core characteristic of deaminases, are conserved. It has been shown that their mutations completely abolish A-to-I editing activity (Lai et al., 1995; Liu and Samuel, 1996). Further, C^{966} and C^{1036} , which are believed to play a role in zinc coordination along with H^{910} , are necessary for ADAR1 deaminase activity and are also conserved in *D. rotundus* (Lai et al., 1995). Moreover, as in other mammals, the lysine residues crucial for both RNA binding and enzymatic activity, present in the core sequence of each of the dsRBD domains (K^{554} , K^{665} , and K^{777}) are conserved (Fierro-Monti and Mathews, 2000; Liu and Samuel, 1996; McCormack et al., 1994).

To test the functionality of the ISG system upon viral infection in our bat model, expression 331 332 of the characterized ISGs was examined following transfection of FLuDero cells with poly(I:C). The induction profile of the ISGs characterized in our bat model does not match 333 that obtained by Zhou and colleagues (Zhou et al., 2013) on lung cells from P. alecto after 334 335 poly(I:C) transfection. Although we also showed an induction of OAS1 and PKR following poly(I:C) transfection, they found higher and earlier induction of PKR as compared to OAS1. 336 The discrepancy between this previous study and our results is probably due to intrinsic 337 factors specific to the bat species leading to distinct expression profiles. Indeed, it has recently 338 been reported that the up-regulation of ISGs was not only lineage- but also species-specific 339 when comparing the megabats and the microbats (Shaw et al., 2017). In addition, the higher 340 induction of OAS1a and OAS1b, as compared to ADAR1 and PKR, may be due to the 341 presence of multiple IFN-stimulated response elements (ISREs) in the OAS1 promoter, as 342 described in P. alecto (Zhou et al., 2013). This can conveniently allow bats to mount a more 343 robust expression of OAS1 rather than of ADAR1 or PKR. In fact, we previously showed an 344 induction of expression of IFNB in poly(I:C)-transfected FLuDero, reaching a peak at 24 h 345 346 (Sarkis et al., 2018). Interestingly, the expression kinetics of the three ISGs characterized was similar to that of IFNB, suggesting that these proteins are induced in an IFNB-dependent 347 manner, acting on the ISREs present in their promoters. It is conceivable that the similar 348

expression levels of ADAR and PKR observed at the RNA level are also observed at the 349 protein level. Accordingly, given the negative regulation of PKR by ADAR, as indicated 350 above, an active PKR might not be in sufficient quantity to exert a proper antiviral action. 351 Therefore, the higher induction of OAS observed, as compared to PKR and ADAR, tends to 352 show the particular importance of the OAS proteins in the antiviral action of IFN in bats. 353 Another interesting observation was the differential expression of OAS1a and OAS1b in our 354 cellular model after poly(I:C) transfection. Interestingly, this feature has already been 355 described in mice (Pulit-Penaloza et al., 2012). It has been shown that the ISRE as well as the 356 overlapping STAT sites are required for Oas1a promoter induction by IFN-β while Oas1b 357 358 expression requires only the ISRE. Furthermore, while OAS1a requires both STAT1 and STAT2 for its upregulation by IFN-β, OAS1b only requires STAT2. Therefore, analyzing the 359 promoter region of these two paralogs should clarify their differential expression in our bat 360 species. 361

We found that the basal transcription level of the ISGs characterized was elevated in the 362 363 FLuDero cells. This observation is consistent with previous results showing that ISGs are constitutively expressed in bats and suggests that bat cells are equipped to mount a rapid 364 defense against viral infections (Cruz-Rivera et al., 2018; Shaw et al., 2017; Zhou et al., 365 2016). In addition to their already significant levels of expression in the absence of treatment, 366 these ISGs can be further enhanced in response to poly(I:C). Together these results tend to 367 prove that these ISGs are functional and must play an important antiviral role in D. rotundus. 368 Further work is therefore necessary to elucidate their role during viral infection, explore the 369 mechanisms underlying their unique expression profiles and determine whether or not they 370 contribute to the unique ability of bats to manage viral infection. 371

373 Acknowledgments

This study was conducted within the CAROLIA and BATIMMUNE programs. CAROLIA 374 was supported by European funds (ERDF/FEDER) and assistance from the Région Guyane 375 376 and the Direction Régionale pour la Recherche et la Technologie. BATIMMUNE was funded by the Institut Pasteur through a Transversal Research Program (PTR499). This study also 377 received a European Commission "REGPOT-CT-2011-285837-STRonGer" grant within the 378 FP7 and an "Investissement d'Avenir" grant managed by the Agence Nationale de la 379 Recherche (CEBA, Ref. ANR-10-LABEX-25-01). The funders had no role in study design, 380 data collection and analysis, decision to publish, or preparation of the manuscript. 381

382

383 Competing Interests

384 The authors declare that they have no competing interests.

386 **References**

Arnaud, N., Dabo, S., Maillard, P., Budkowska, A., Kalliampakou, K.I., Mavromara, P.,
Garcin, D., Hugon, J., Gatignol, A., Akazawa, D., Wakita, T., Meurs, E.F., 2010. Hepatitis C
Virus Controls Interferon Production through PKR Activation. PLoS ONE 5.
https://doi.org/10.1371/journal.pone.0010575

391

392 Athanasiadis, A., Placido, D., Maas, S., Brown, B.A., Lowenhaupt, K., Rich, A., 2005. The Crystal Structure of the Z^β Domain of the RNA-editing Enzyme ADAR1 Reveals Distinct 393 Conserved Surfaces Among Z-domains. J. Mol. Biol. 351. 496-507. 394 395 https://doi.org/10.1016/j.jmb.2005.06.028

396

Baker, M.L., Schountz, T., Wang, L.-F., 2013. Antiviral immune responses of bats: a review.
Zoonoses Public Health 60, 104–116. https://doi.org/10.1111/j.1863-2378.2012.01528.x

399

Bazak, L., Haviv, A., Barak, M., Jacob-Hirsch, J., Deng, P., Zhang, R., Isaacs, F.J., Rechavi,
G., Li, J.B., Eisenberg, E., Levanon, E.Y., 2014. A-to-I RNA editing occurs at over a hundred
million genomic sites, located in a majority of human genes. Genome Res. 24, 365–376.
https://doi.org/10.1101/gr.164749.113

404

Bonnet, M.C., Daurat, C., Ottone, C., Meurs, E.F., 2006. The N-terminus of PKR is
responsible for the activation of the NF-κB signaling pathway by interacting with the IKK
complex. Cell. Signal. 18, 1865–1875. https://doi.org/10.1016/j.cellsig.2006.02.010

Borden, E.C., Sen, G.C., Uze, G., Silverman, R.H., Ransohoff, R.M., Foster, G.R., Stark,
G.R., 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev.
Drug Discov. 6, 975–990. https://doi.org/10.1038/nrd2422

412

Clerzius, G., Gélinas, J.-F., Daher, A., Bonnet, M., Meurs, E.F., Gatignol, A., 2009. ADAR1
Interacts with PKR during Human Immunodeficiency Virus Infection of Lymphocytes and
Contributes to Viral Replication. J. Virol. 83, 10119–10128.
https://doi.org/10.1128/JVI.02457-08

417

Cruz-Rivera, P.C.D.L., Kanchwala, M., Liang, H., Kumar, A., Wang, L.-F., Xing, C.,
Schoggins, J.W., 2018. The IFN Response in Bats Displays Distinctive IFN-Stimulated Gene
Expression Kinetics with Atypical RNASEL Induction. J. Immunol. 200, 209–217.
https://doi.org/10.4049/jimmunol.1701214

422

Dabo, S., Meurs, E.F., 2012. dsRNA-Dependent Protein Kinase PKR and its Role in Stress,
Signaling and HCV Infection. Viruses 4, 2598–2635. https://doi.org/10.3390/v4112598

426 Der, S.D., Zhou, A., Williams, B.R., Silverman, R.H., 1998. Identification of genes
427 differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.
428 Proc. Natl. Acad. Sci. U. S. A. 95, 15623–15628.

429

430 Dey, M., Cao, C., Sicheri, F., Dever, T.E., 2007. Conserved Intermolecular Salt Bridge 431 Required for Activation of Protein Kinases PKR, GCN2, and PERK. J. Biol. Chem. 282,

432 6653–6660. https://doi.org/10.1074/jbc.M607897200

- Doria, M., Neri, F., Gallo, A., Farace, M.G., Michienzi, A., 2009. Editing of HIV-1 RNA by
 the double-stranded RNA deaminase ADAR1 stimulates viral infection. Nucleic Acids Res.
 27, 5848, 5858, https://doi.org/10.1002/nor/glup604
- 436 37, 5848–5858. https://doi.org/10.1093/nar/gkp604 437
- Elkhateeb, E., Tag-El-Din-Hassan, H.T., Sasaki, N., Torigoe, D., Morimatsu, M., Agui, T.,
 2016. The role of mouse 2',5'-oligoadenylate synthetase 1 paralogs. Infect. Genet. Evol. 45,
 393–401. https://doi.org/10.1016/j.meegid.2016.09.018
- 441
- Fierro-Monti, I., Mathews, M.B., 2000. Proteins binding to duplexed RNA: one motif,
 multiple functions. Trends Biochem. Sci. 25, 241–246. https://doi.org/10.1016/S09680004(00)01580-2
- 445
- Garaigorta, U., Chisari, F.V., 2009. Hepatitis C Virus Blocks Interferon Effector Function by
 Inducing PKR Phosphorylation. Cell Host Microbe 6, 513–522.
 https://doi.org/10.1016/j.chom.2009.11.004
- 449
- García, M.A., Meurs, E.F., Esteban, M., 2007. The dsRNA protein kinase PKR: Virus and
 cell control. Biochimie 89, 799–811. https://doi.org/10.1016/j.biochi.2007.03.001.
- 452
- Guénet, J.L., Benavides, F., Panthier, J., Montagutelli, X., 2015. Genetics of the Mouse.
 Springer Berlin Heidelberg. XVII Chapters, 408 pages. https://doi.org/10.1007/978-3-66244287-6.
- George, C.X., Samuel, C.E., 1999. Characterization of the 5'-flanking region of the human
 RNA-specific adenosine deaminase ADAR1 gene and identification of an interferon-inducible
 ADAR1 promoter. Gene 229, 203–213.
- Ghosh, A., Sarkar, S.N., Guo, W., Bandyopadhyay, S., Sen, G.C., 1997. Enzymatic activity of
 2'-5'-oligoadenylate synthetase is impaired by specific mutations that affect oligomerization
 of the protein. J. Biol. Chem. 272, 33220–33226.
- 464

- Goodman, R.A., Macbeth, M.R., Beal, P.A., 2012. ADAR proteins: structure and catalytic
 mechanism. Curr. Top. Microbiol. Immunol. 353, 1–33. https://doi.org/10.1007/82_2011_144
- He, X., Korytář, T., Zhu, Y., Pikula, J., Bandouchova, H., Zukal, J., Köllner, B., 2014.
 Establishment of Myotis myotis cell lines--model for investigation of host-pathogen interaction in a natural host for emerging viruses. PloS One 9, e109795.
 https://doi.org/10.1371/journal.pone.0109795
- 472
- Herbert, A., Alfken, J., Kim, Y.-G., Mian, I.S., Nishikura, K., Rich, A., 1997. A Z-DNA
 binding domain present in the human editing enzyme, double-stranded RNA
 adenosine deaminase. Proc. Natl. Acad. Sci. U. S. A. 94, 8421–8426.
- 476
- Justesen, J., Hartmann, R., Kjeldgaard, N.O., 2000. Gene structure and function of the 2'-5'oligoadenylate synthetase family. Cell. Mol. Life Sci. CMLS 57, 1593–1612.
- 479
- 480 Kim, Y.-G., Lowenhaupt, K., Schwartz, T., Rich, A., 1999. The Interaction between Z-DNA 481 and the Zab Domain of Double-stranded RNA Adenosine Deaminase Characterized Using
- 482
 Fusion
 Nucleases.
 J.
 Biol.
 Chem.
 274,
 19081–19086.

 483
 https://doi.org/10.1074/jbc.274.27.19081
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1</td

484

Kristiansen, H., Gad, H.H., Eskildsen-Larsen, S., Despres, P., Hartmann, R., 2011. The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities.
J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res. 31, 41–47. https://doi.org/10.1089/jir.2010.0107

Lai, F., Drakas, R., Nishikura, K., 1995. Mutagenic Analysis of Double-stranded RNA
Adenosine Deaminase, a Candidate Enzyme for RNA Editing of Glutamate-gated Ion
Channel Transcripts. J. Biol. Chem. 270, 17098–17105.
https://doi.org/10.1074/jbc.270.29.17098

494

489

Letunic, I., Doerks, T., Bork, P., 2015. SMART: recent updates, new developments and status
in 2015. Nucleic Acids Res. 43, D257-260. https://doi.org/10.1093/nar/gku949

Levy, D.E., Marié, I., Smith, E., Prakash, A., 2002. Enhancement and diversification of IFN
induction by IRF-7-mediated positive feedback. J. Interferon Cytokine Res. Off. J. Int. Soc.
Interferon Cytokine Res. 22, 87–93. https://doi.org/10.1089/107999002753452692

501

505

509

Liu, Y., Samuel, C.E., 1996. Mechanism of interferon action: functionally distinct RNAbinding and catalytic domains in the interferon-inducible, double-stranded RNA-specific
adenosine deaminase. J. Virol. 70, 1961–1968.

Malathi, K., Dong, B., Gale, M., Silverman, R.H., 2007. Small self-RNA generated by RNase
L amplifies antiviral innate immunity. Nature 448, 816–819.
https://doi.org/10.1038/nature06042

Malathi, K., Paranjape, J.M., Bulanova, E., Shim, M., Guenther-Johnson, J.M., Faber, P.W.,
Eling, T.E., Williams, B.R.G., Silverman, R.H., 2005. A transcriptional signaling pathway in
the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L. Proc. Natl. Acad. Sci.
U. S. A. 102, 14533–14538. https://doi.org/10.1073/pnas.0507551102

514

Mannion, N., Arieti, F., Gallo, A., Keegan, L.P., O'Connell, M.A., 2015. New Insights into
the Biological Role of Mammalian ADARs; the RNA Editing Proteins. Biomolecules 5,
2338–2362. https://doi.org/10.3390/biom5042338

Marié, I., Blanco, J., Rebouillat, D., Hovanessian, A.G., 1997. 69-kDa and 100-kDa isoforms
of interferon-induced (2'-5')oligoadenylate synthetase exhibit differential catalytic
parameters. Eur. J. Biochem. 248, 558–566.

522

518

McCormack, S.J., Ortega, L.G., Doohan, J.P., Samuel, C.E., 1994. Mechanism of Interferon
Action Motif I of the Interferon-Induced, RNA-Dependent Protein Kinase (PKR) Is Sufficient
to Mediate RNA-Binding Activity. Virology 198, 92–99.
https://doi.org/10.1006/viro.1994.1011

527

Meurs, E., Chong, K., Galabru, J., Thomas, N.S.B., Kerr, I.M., Williams, B.R.G.,
Hovanessian, A.G., 1990. Molecular cloning and characterization of the human doublestranded RNA-activated protein kinase induced by interferon. Cell 62, 379–390.
https://doi.org/10.1016/0092-8674(90)90374-N

- Meurs, E.F., Watanabe, Y., Kadereit, S., Barber, G.N., Katze, M.G., Chong, K., Williams, 533 B.R., Hovanessian, A.G., 1992. Constitutive expression of human double-stranded RNA-534 activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 535 and partial resistance to encephalomyocarditis virus growth. J. Virol. 66, 5805–5814. 536
- 537 538 Moratelli, R., Calisher, C.H., 2015. Bats and zoonotic viruses: can we confidently link bats emerging deadly viruses? Mem. Inst. Oswaldo Cruz 539 with https://doi.org/10.1590/0074-02760150048
- 540 541
- Pulit-Penaloza, J.A., Scherbik, S.V., Brinton, M.A., 2012. Activation of Oas1a gene 542 expression by type I IFN requires both STAT1 and STAT2 while only STAT2 is required for 543 Oas1b activation. Virology 425, 71–81. https://doi.org/10.1016/j.virol.2011.11.025 544

110.

1 - 22.

- 546 Saraste, M., Sibbald, P.R., Wittinghofer, A., 1990. The P-loop--a common motif in ATP- and 547 GTP-binding proteins. Trends Biochem. Sci. 15, 430–434.
- 548 Sarkar, S.N., Miyagi, M., Crabb, J.W., Sen, G.C., 2002. Identification of the substrate-binding 549 550 sites of 2'-5'-oligoadenylate synthetase. J. Biol. Chem. 277, 24321-24330. 551 https://doi.org/10.1074/jbc.M110202200
- 552

557

560

545

- 553 Sarkis, S., Lise, M.-C., Darcissac, E., Dabo, S., Falk, M., Chaulet, L., Neuveut, C., Meurs, E.F., Lavergne, A., Lacoste, V., 2018. Development of molecular and cellular tools to 554 decipher the type I IFN pathway of the common vampire bat. Dev. Comp. Immunol. 81, 1–7. 555 556 https://doi.org/10.1016/j.dci.2017.10.023
- Sen, G.C., 2001. Viruses and Interferons. Annu. Rev. Microbiol. 55, 255-281. 558 559 https://doi.org/10.1146/annurev.micro.55.1.255
- Shaw, A.E., Hughes, J., Gu, Q., Behdenna, A., Singer, J.B., Dennis, T., Orton, R.J., Varela, 561 M., Gifford, R.J., Wilson, S.J., Palmarini, M., 2017. Fundamental properties of the 562 mammalian innate immune system revealed by multispecies comparison of type I interferon 563 responses. PLOS Biol. 15, e2004086. https://doi.org/10.1371/journal.pbio.2004086 564 565
- Silverman, R.H., 2003. Implications for RNase L in Prostate Cancer Biology. Biochemistry 566 (Mosc.) 42, 1805–1812. https://doi.org/10.1021/bi027147i 567
- 569 Tag-El-Din-Hassan, H.T., Sasaki, N., Moritoh, K., Torigoe, D., Maeda, A., Agui, T., 2012. The chicken 2'-5' oligoadenylate synthetase A inhibits the replication of West Nile virus. Jpn. 570 J. Vet. Res. 60, 95–103. 571
- 572

- 573 Tamura, K., Stecher, G., Peterson, D., Filipski, A., Kumar, S., 2013. MEGA6: Molecular 574 Evolutionary Genetics Analysis version 6.0. Mol. Biol. Evol. 30, 2725–2729. https://doi.org/10.1093/molbev/mst197 575
- 576
- 577 Williams, B.R.G., 2001. Signal Integration via PKR. Sci STKE 2001, re2-re2. 578 https://doi.org/10.1126/stke.2001.89.re2
- 579
- Xiang, Y., Wang, Z., Murakami, J., Plummer, S., Klein, E.A., Carpten, J.D., Trent, J.M., 580 581 Isaacs, W.B., Casey, G., Silverman, R.H., 2003. Effects of RNase L mutations associated with 582 prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res. 63, 6795–6801.

Yamamoto, Y., Sono, D., Sokawa, Y., 2000. Effects of specific mutations in active site motifs
of 2',5'-oligoadenylate synthetase on enzymatic activity. J. Interferon Cytokine Res. Off. J.
Int. Soc. Interferon Cytokine Res. 20, 337–344. https://doi.org/10.1089/107999000312496

- Zhou, P., Cowled, C., Wang, L.-F., Baker, M.L., 2013. Bat Mx1 and Oas1, but not Pkr are
 highly induced by bat interferon and viral infection. Dev. Comp. Immunol. 40, 240–247.
 https://doi.org/10.1016/j.dci.2013.03.006
- 590

- Zhou, P., Tachedjian, M., Wynne, J.W., Boyd, V., Cui, J., Smith, I., Cowled, C., Ng, J.H.J.,
- Mok, L., Michalski, W.P., Mendenhall, I.H., Tachedjian, G., Wang, L.-F., Baker, M.L., 2016.
 Contraction of the type I IFN locus and unusual constitutive expression of IFN-α in bats.
- 593 Contraction of the type I IFN locus and unusual constitutive expression of IFN- α in 594 Proc. Natl. Acad. Sci. U. S. A. 113, 2696–2701. https://doi.org/10.1073/pnas.1518240113
- 595

Figure 1. Amino acid alignment of D. rotundus OAS1 paralogs and other mammalian 596 species. The two important signature domains, NTP-transf_2 and OAS1_C in D. rotundus 597 OAS1a and OAS1b are highlighted with solid arrows. Amino acid sequence motifs important 598 for the enzyme activity are shown in boxes. The orange rectangle represents the Serine 599 residue in the putative helical turn, the adjacent Serine, which is either Serine or Threonine 600 (Rune Hartmann et al., 2003 Molecular cell). Inverted triangle: one of the signature features 601 of the nucleotidyl transferase superfamily is a conserved triad of aspartic acids predicted to 602 coordinate the catalytically active magnesium ions. The multi-alignment was performed with 603 the ClustalW program using default parameters. Dashes indicate gaps in the amino acid 604 alignment. Abbreviations: MIOAS1: Myotis lucifigus OAS1 (XM_014464612), MIOAS11: 605 606 Myotis lucifigus OAS1-like (XM_014462497), HsOAS1: Homo sapiens OAS1 (BC000562), SsOAS1: Sus (NM 214303), MmOAS1a-h: Mus 607 scrofa musculus OAS1a-h (XM_006530330, BC012877, NM_033541, BC052835, BC053721, BC116433, BC018470, 608 609 NM_145228).

Figure 2. Amino acid alignments of D. rotundus ADAR1 and PKR with their homologs 610 from other mammalian species. a) All motifs required for ADAR1 activity are highlighted 611 612 with solid arrows, including two $Z\alpha$ domains at the N-terminus, followed by three doublestranded RNA-binding motifs (dsRBM), dsRBM1, 2 and 3, and a catalytic deaminase domain 613 at its C-terminus. b) PKR contains two dsRBM highlighted in yellow (dsRBM1) and light 614 gray (dsRBM2) followed by a basic region (dark gray) and subdomain sequences in boxes 615 found in the catalytic region highlighted with solid arrows, green represents the repeat 616 617 sequence in human PKR not present in D. rotundus, other bat species and mice PKR. An insert region at the C-terminal of the subdomain IV is highlighted in blue. The multi-618 alignments were performed with the ClustalW program using default parameters. Dashes 619 620 indicate gaps in the amino acid alignments. Abbreviations: PaADAR1/PKR: Pteropus alecto

ADAR1/PKR (XM_015598363/NM_0012910168), HsADAR1/PKR: *Homo sapiens* ADAR1/PKR
(NM_001111/XM_011532987), MmADAR1/PKR: *Mus musculus* ADAR1/PKR
(NM_019655/NM_011163).

Figure 3. Phylogenetic trees generated from amino acid sequence alignments of OAS1, **ADAR1 and PKR from** *D. rotundus* **and other mammals.** Phylogenetic trees were generated based on (**a**) the alignment of partial amino acid sequence of the mammalian OAS1, and the full-length protein sequence of (**b**) ADAR1 and (**c**) PKR. The trees were inferred using the Bayesian method with the JTT + G model. Sequence identifiers include the NCBI accession number. Posterior probabilities of the Bayesian analysis (>50%) are shown next to each node. The scale bar indicates amino acid substitutions per site.

Figure 4. Poly(I:C) transfection induces expression of ISGs. Time-course fold induction of (a) OAS1a, (b) OAS1b, (c) ADAR1 and (d) PKR in FLuDero cells upon poly(I:C) transfection. ISGs mRNA were assessed by RTqPCR. Data were normalized against β-actin. Cells were stimulated with 20 µg/mL of poly(I:C) and harvested at the indicated time points. Data represent the mean values of three separate experiments, and the error bars represent standard deviations (SD).

Figure 5. Quantitative mRNA expression of OAS1a, OAS1b, ADAR1 and PKR. Time course mRNA expression levels of (**red**) OAS1a, (**green**) OAS1b, (**blue**) ADAR1 and (**purple**) PKR were assessed by RTqPCR in FLuDero cells upon poly(I:C) transfection. Cells were stimulated with 20 μ g/mL of poly(I:C) and harvested at the indicated time points. The expression was normalized to the housekeeping gene β-actin. Data represent the mean values of three separate experiments.



	K-R rich region	
DrOAS1a	TELORAFIKORPTKLKSLIRLVKHWYOMCKEKLGKPLPPOYALELLTVYAWERGNOE-TI	239
DrOAS1b	TELORAFIKORPPKLKSLIRLVKYWYQECKOKLGOPLPFQYALELLTVYAWERGSKE-AD	266
MlOAS1	TELQRAFIKQRPAKLKSLIRLVKHWYQKCKEKPGQSLPPQYALELLTVYAWERAGRE-TD	268
MlOAS11	TELQKAFIRQRPTKLKSLIRLVKHWYQLCKQRLGKPLPPQYALELLTVHAWERGCKE-TY	235
HsOAS1	TELQRDFIKQRPTKLKSLIRLVKHWYQNCKKKLG-KLPPQYALELLTVYAWERGSMK-TH	247
SsOAS1	TELQRDFIRNRPTKLKSLIRLVKHWYQTCKKTHGNKLPPQYALELLTVYAWEQGSRK-TD	248
MmOAS1a	TELQRNFIKQRPTKLKSLIRLVKHWYQLCKEKLGKPLPPQYALELLTVFAWEQGNGC-YE	250
MmOAS1b	MGIRKYFINCRPTKLKRLIHLVTHWYQLCKEKLGDPLPPQYALELLTVYAWEYGSRV-TK	245
MmOAS1c	TDIHQNFNRYRAPKLWNLIRLVKHWYQLCKEKLREPLPPQYALELLTVYVWEHSNKNQEK	255
MmOAS1d	TDIHQSFIRTRAPKLWNLIRLVKHWYQLCKEKLRGPLPPQYALELLTVYVWEYGIHENPG	255
MmOAS1e	TDIHQSFIRYRAPKLWNLIRLVKHWYQLCKEKLRGPLPPQYALELLTVYVWEFGVQDSFG	255
MmOAS1f	TDIHQSFIEDRAPKLKNLIRLVKHWYQLCKEKLGKPLPPQYALELLTVYAWESGSRD-CE	254
MmOAS1g	TEIQRNFIKQRPTKLKSLIRLVKHWYQLCKEKLGKPLPPQYALELLTVYAWEQGNGC-NE	250
MmOAS1h	MELQQDFIWKRPCELKNLICLVKHWYQLCKEKLREPLPPQYALELLTVYAWEHELPDKHE	262
	OAS1 C	
DrOAS1a	FSTAOGFOTVLELVMNYOOLLIYWTKYYDFENPVIGOYLRMOLKKPRPVILDPADPTGNV	299
DrOAS1b	FVTAOGFOTVLELVVDYRKLCIYWTKYYDINHSVIGPYLRROLOKPRPVILDPADPTGNI	326
MlOAS1	FITAQGFRTVLELVMNYRQLCIHWTQYYDCSHPEIGPYVRRQLQKPRPVILDPADPTGNV	328
MlOAS11	FSTAEGFRTVLELVVHYRQLCVYWTKYYDFENPVICQYLMTQLEQPMPVILDPADPTGNV	295
HsOAS1	FNTAQGFRTVLELVINYQQLCIYWTKYYDFKNPIIEKYLRRQLTKPRPVILDPADPTGNL	307
SsOAS1	FSTAQGFQTVLELVLKHQKLCIFWEAYYDFTNPVVGRCMLQQLKKPRPVILDPADPTGNV	308
MmOAS1a	FNTAQGFRTVLELVINYQHLRIYWTKYYDFQHQEVSKYLHRQLRKARPVILDPADPTGNV	310
MmOAS1b	FNTAQGFRTVLELVTKYKQLRIYWTVYYDFRHQEVSEYLHQQLKKDRPVILDPADPTRNI	305
MmOAS1c	VTTAKNFRTFLELVAYYKNLRIYWTWYYDFRHQEVCAYLCRQLKKARPLILDPADPTRNV	315
MmOAS1d	LHTAQCFRTVLELVTKYKRLRIYWTWCYDFQH-EISDYLQGQIKKARPLILDPADPTRNV	314
MmOAS1e	LHAAQCFRTVLELVTKYKCLLIYWTWFYDFRP-EISDYLHGQIKKARPLILDPADPTRNV	313
MmOAS1f	FNTAQGFRTVLELVTKYKWLRIYWTVYYDFRKTKVSEYLHKMLQKVRPVILDPADPTRNV	314
MmOAS1q	FNTAOGFRTVLELVINYQHLRIYWTKYYDFOHKEVSKYLHRQLRKARPVILDPADPTGNV	310
MmOAS1h	TQTARGFRTVLELITKYLCLRIYWTLYYDVLHEQVNAYLYSQVKRVSPLILDPADPTWNV	322
	CFK	
	L <u> </u>	
DrOAS1a	AAGD-SGSWPRLAQEAKAWLSYQCFKNWDGSPVGSWYIPLPENSEDGGTCAIL	351
DrOAS1b	GADNPPRGWERPAGQARAWLTYFCFKKWDGSPVGSWSIQI	366
M10AS1	AGGKPER-WEPLAGEARVWMTYFCFRKGDGSPVGSWDIKA	367
M10AS11	AGGGGWQRLAQEAAAWMTYFCLKNWDGSPVDSW	328
HsOAS1	GGGD-PKGWRQLAQEAEAWLNYFCFKNWDGSPVSSWILLVRPPASSLPFIPAPLHEA	363
SsOAS1	GGGD-THSWQRLAQEARVWLGYFCCKNLDGSLVGAWTMLQKI	349
MmOAS1a	AGGN-PEGWRRLAEEADVWLWYPCFIKKDGSRVSSWDVPECRLLTRLCYFSLQTVVPVPF	369
MmOAS1b	AGLN-PKDWRRLAGEAAAWLQYPCFKYRDGSPVCSWEVPTEVAVPTKYLFCRIFWLLFWS	364
MmOAS1c	AGSD-LQAWDLLAKEAQTWMQSSCFRNCDMSFVPTWDLSPERQECAFQ	362
MmOAS1d	AGSD-LQAWDLLAKEAQIWIDSTFFTNHDMSIVEAWEVMPERQECVFL	361
MmOAS1e	AGSD-LQAWDLLAKEAQTWIHSNFFRNCDMSLVNGWEVSPEKQ	355
MmOAS1f	AGTN-LLGWGLLAKEAAIWLQSSCFRNCDTCLVGPWGVPMKVEIPQDCVLL	364
MmOAS1g	AGGN-PEGWRRLAEEADVWLWYFCFMKNDGSRVSSWDVPTVVPVPFEQEEENWTCILL	367
MmOAS1h	AGLN-LQGWCILAEEAKAWLDYECFKNRDGSRVSSWDVPPDKKGFVFL	369

Figure 1.



DrADARI HSKKQGKQEAADAALRVLIGENEKAERMGFTEL			
PaADARI HSKKQGKQEAADAALRVLIGESEKAERMGFTEL	DrADAR1	HSKKOGKOFAADAALRVLIGENEKAERMGETELP	755
HSADARI HSKKQGKQEAADAALRVLIGENEKAERMGFTEVTPVTGASLRRTMLLLSRSPEAQPKTLP 834 MmADARI HSKKQGKQEAADAALRVLIGENEKAERMGFTEVTPVTGASLRRTMLLLSRSPEAQPKTLP 757 DTADARI HSKKQGKQEAADAALRVLIGENEKAERMGFTEVTPVTGASLRRTMLLLSRSPEAQPKTLP 757 DTADARI LTGSTFHQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVSLGTGNRCV 811 HSADARI LTGSTFHQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVSLGTGNRCV 811 LTGSTFHQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVSLGTGNRCV 817 DTADARI LGSTFHQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDMGVVSLGTGNRCV 817 DTADARI KGDSLSLKGETVNDCHAEIISRGFIRFLYSLGRKILAAIIMKKDSEDMGVVSLGTGNRCV 817 DTADARI KGDSLSLKGETVNDCHAEIISRGFIRFLYSELMKYNPOTAKDSIFEPAKGEKLQIKKT 875 RADARI KGDSLSLKGETVNDCHAEIISRGFIRFLYSELMKYNPOTAKDSIFEPAKGEKLQIKKT 877 DTADARI KGDSLSLKGETVNDCHAEIISRGFIRFLYSELMKYNPOTAKDSIFEPAKGEKLQIKKT 877 DTADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 935 PAADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 DTADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 DTADARI SDIVPTWDGIRLGERLFMSCSDKILLRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PAADARI SDIVPTWDGIRLGERLFMSCSDKILLRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 DTADARI SDIVPTWDGIRLGERLFMSCSDKILLRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DTADARI SDIVPTWDGIRLGERLFMSCSDKILLRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 1074 MMADARI SDIVPTWDGIRLGERLFMSCSDKILLRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 1055 HSADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 DTADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 DTADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 DTADARI DLEILDGTRGTVDGPRNELSRVSKNIFLLFKKLCSFRARDLKLSVGEAKKAARDVEA 1111 HSADARI DLEILDGTRGTVDGPRNELSRVSKNIFLLFKKLCSFRARDLKLSVGEAKKAARDVET 1114 MADARI DLEILDGTRGTVDGPRNELSRVSKNIFLLFKKLCSFRARDLLKLSVGEAKKAARDVET 1114 MADARI DLEILDGTRGTVDGPRNELSRVSKNIFLLFKKLCSFRARDLLLSVGEAKKAARDVET 1114 PAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1246	PaADAR1	HSKKOGKOEAADAALRVLIGESEKAERMGFTELP	751
MmaDAR1 HSKKQGKQDAADAALRVLIGESEKAEQLGFAELP 757 DrADAR1 LTGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVVSLGTGNRCV 815 PaADAR1 LTGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVVSLGTGNRCV 811 HsaDAR1 LTGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVVSLGTGNRCV 811 HsaDAR1 LTGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVVSLGTGNRCV 817 DrADAR1 LSGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVSLGTGNRCV 817 DrADAR1 KGDSLSLKGETVNDCHAEIISRGFIRFLYSELMKYNSQTAKDSIFEPARGGEKLQIKKT 871 PaADAR1 KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNSQTAKDSIFEPAKGGEKLQIKKT 871 MmADAR1 KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNSQTAKDSIFEPAKGGEKLQIKKT 871 PaADAR1 KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNSQTAKDSIFEPAKGGEKLQIKKT 871 PaADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 PaADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 PAADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTESKHYPVFENPKQGKLRTKVENGEGTIPVE 931 PAADAR1 VSFHLYISTAPCGDGALFDKSCSDKLCWNVLGLQGALLTHFLQPVYLKSVTLGVLFSQG 995 PAADAR1 SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGVLFSQG 991	HsADAR1	HSKKOGKOEAADAALRVLIGENEKAERMGFTEVTPVTGASLRRTMLLLSRSPEAOPKTLP	834
DrADARI DrADARI LTGSTFHDQIAMLSHRCPNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVVSLGTGNRCV 811 HSADARI LTGSTFHDQIAMLSHRCPNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVSLGTGNRCV 814 HSADARI LGSTFHDQIAMLSHRCPNALTNSFQPSLLGRKILAAIIMKKDSEDMGVVSLGTGNRCV 817 DrADARI KGDSLSLKGETVNDCHABIISRGFIRFLYNELMKYSPQTAKDSIFEPARGGEKLQIKKT 817 DrADARI KGDSLSLKGETVNDCHABIISRGFIRFLYSELMKYNSQTAKDSIFEPARGGEKLQIKKT 817 DrADARI KGDSLSLKGETVNDCHABIISRGFIRFLYSELMKYNSQTAKDSIFEPARGGEKLQIKKT 817 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 935 PAADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 932 PADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 934 DrADARI SDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PADARI SDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI SDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1057 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1057 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1057 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1057 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1057 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1057 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1057 DrADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRRRRDLLKLSYGEAKAARDVET 1117 MMADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRRRRDLLKLSYGEAKAARDVET 1117 PAADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1144 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKGLKD	MmADAR1	HSKKQGKQDAADAALRVLIGESEKAEQLGFAELP	757
DrADAR1 LTGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVVSLGTGNRCV \$15 PAADAR1 LTGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVVSLGTGNRCV \$11 HSADAR1 LTGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVVSLGTGNRCV \$814 MmADAR1 LSGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDMGVVVSLGTGNRCV \$817 DrADAR1 KGDSLSLKGETVNDCHAEIISRRGFIRFLYNELMKYSPQTAKDSIFEPARGGEKLQIKKT \$75 PAADAR1 KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNPOTAKDSIFEPAKGGEKLQIKKT \$71 MmADAR1 KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNPOTAKDSIFEPAKGGEKLQIKKT \$77 DrADAR1 KGDSLSLKGETVNDCHAEIISRGFIRFLYSELMKYNPOTAKDSIFEPAKGGEKLQIKKT \$77 DrADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE \$935 PaADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE \$937 MmADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE \$937 Catalytic deaminase domain \$940 DrADAR1 VSFHLYISTAPCGDGALFDKSCSDKILKNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG \$951 PAADAR1 SSDIVPTWDGIRLGERLRTMSCSDKILRNVVLGLQGALLTHFLQPVYLKSVTLGYLFSQG \$951 PAADAR1 SSDIVPTWDGIRLGERLRTMSCSDKILRNVVLGLQGALLTHFLQPYYLKSVTLGYLFSQG \$97			
PaADARI LTGSTFHDQIAMLSHRCFNLTNSFQPSLLGRKILAAIIMKKDSEDGVVSLGTGNRCV 814 HaADARI LTGSTFHDQIAMLSHRCFNLTNSFQPSLLGRKILAAIIMKKDSEDGVVSLGTGNRCV 894 MmADARI LSGSTFHDQIAMLSHRCFNLTNSFQPSLLGRKILAAIIMKKDSEDGMGVVSLGTGNRCV 817 DrADARI KGDSLSLKGETVNDCHAEIISRGFIRFLYNELMKYSPQTAKDSIFEPARGEKLQIKKT 871 PaADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNPQTAKDSIFEPAKGGEKLQIKKT 871 MmADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNPQTAKDSIFEPAKGGEKLQIKKT 871 MmADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNPQTAKDSIFEPAKGGEKLQIKKT 871 MmADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNNSQTAKDSIFEPAKGGEKLQIKKT 877 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 HAADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 HAADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 931 DrADARI VSFHLYISTAPCGDGALFDKSCSDKILCMNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PAADARI SSDIVPTWDGIRLGERLRTMSCSDKILCMNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PAADARI SSDIVPTWDGIRLGERLRTMSCSDKILRMNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGQ	DrADAR1	LTGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVVSLGTGNRCV	815
HSADARI LTGSTFHDQIAMLSHRCFNILTNSFQPSLLGRKILAAIIMKKDSEDMGVVVSLGTGNRCV 894 MmADARI LGGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKRDPEDMGVVVSLGTGNRCV 817 DrADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYNELMKYSQTAKDSIFEPAKGGEKLQIKKT 875 PAADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNPQTAKDSIFEPAKGGEKLQIKKT 871 MMADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNPQTAKDSIFEPAKGGEKLQIKKT 871 MMADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNPQTAKDSIFEPAKGGEKLQIKKT 877 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIFVE 935 PAADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIFVE 931 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIFVE 931 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIFVE 931 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PAADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PAADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALTHFLQPVYLKSVTLGYLFSQG 997 DFADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1134 HMMADARI HLTRAICCRVTRDGSAFEDGLRPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1134 HMMADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDVET 1115 PAADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDVET 1114 PAADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDVET 1114 PAADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDVET 1114 PAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143	PaADAR1	LTGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKKDSEDLGVVVSLGTGNRCV	811
MmaDAR1 LSGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKRDPEDMGVVVSLGTGNRCV 817 DrADAR1 KGDSLSLKGETVNDCHABIISRGFIRFLYNELMKYSPQTAKDSIFEPARGGEKLQIKKT 875 PaADAR1 KGDSLSLKGETVNDCHABIISRGFIRFLYSELMKYNPQTAKDSIFEPAKGGEKLQIKKT 871 MmaDAR1 KGDSLSLKGETVNDCHABIISRGFIRFLYSELMKYNPQTAKDSIFEPAKGGEKLQIKKT 871 DrADAR1 KGDSLSLKGETVNDCHABIISRGFIRFLYSELMKYNPQTAKDSIFEPAKGGEKLQIKKT 877 DrADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 935 PaADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 MmADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 MmADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 931 MmADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 937 Catalytic deaminase domain 937 DrADAR1 SSDIVPTMDGIRLGERLRTMSCSDKILRMNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PAADAR1 SSDIVPTMDGIRLGERLRTMSCSDKILRMNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADAR1 HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 PADAR1 HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1057 PAADAR1 H	HsADAR1	LTGSTFHDQIAMLSHRCFNTLTNSFQPSLLGRKILAAIIMKKDSEDMGVVVSLGTGNRCV	894
DrADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYNELMKYSPQTAKDSIFEPARGGEKLQIKKT 875 PaADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNPQTAKDSIFEPARGGEKLQIKKT 871 HsADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNPQTAKDSIFEPARGGEKLQIKKT 871 MmADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNNSQTAKDSIFEPARGGEKLQIKKT 874 MmADARI KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNNSQTAKDSIFEPARGGEKLQIKKT 877 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 HSADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 MmADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 931 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 931 DrADARI VSFHLYISTAPCGDGALFDKSCSDRILESRWYFENPKQGKLRTKVENGEGTIPVE 931 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILLCMNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PaADARI SSDIVPTWDGIRLGERLRTMSCSDKILRMNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 PaADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY <t< td=""><td>MmADAR1</td><td>LSGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKRDPEDMGVVVSLGTGNRCV</td><td>817</td></t<>	MmADAR1	LSGSTFHDQIAMLSHRCFNALTNSFQPSLLGRKILAAIIMKRDPEDMGVVVSLGTGNRCV	817
DrADARI KGDSLSLKGETVNDCHABIISRRGFIRFLYNELMKYSPQTAKDSIFEPARGGEKLQIKKT 875 PaADARI KGDSLSLKGETVNDCHABIISRRGFIRFLYSELMKYNQTAKDSIFEPARGGEKLQIKKT 871 HSADARI KGDSLSLKGETVNDCHABIISRRGFIRFLYSELMKYNQTAKDSIFEPAKGGEKLQIKKT 877 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIFVE 935 PAADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIFVE 931 MMADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIFVE 931 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIFVE 931 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIFVE 931 DrADARI SDIVPTWDGIRLGERLRTMSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIFVE 931 DrADARI SDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALTHFLQPVYLKSVTLGYLFSQG 995 PAADARI SDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALTHFLQPVYLKSVTLGYLFSQG 991 DrADARI SDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALTHFLQPVYLKSVTLGYLFSQG 997 DrADARI SDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALTHFLQPVYLKSVTLGYLFSQG 997 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 DAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 DFADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1057 DFADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDVET 1115 DFADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDVET 1115 DFADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDVET 1114 MMADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDVET 1114 PAADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLLSYGEAKKAARDVET 1114 MAADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDVET 1114 MAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143			
PaADARI KGDSLSLKGETVNDCHAEIISRGFIRFLYSELMKYNPOTAKDSIFEPAKGGEKLQIKKT 871 HsADARI KGDSLSLKGETVNDCHAEIISRGFIRFLYSELMKYNPOTAKDSIFEPAKGGEKLQIKKT 875 MmADARI KGDSLSLKGETVNDCHAEIISRGFIRFLYSELMKYNSOTAKDSIFEPAKGGEKLQIKKT 877 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 935 PaADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 HsADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 937 Catalytic deaminase domain 937 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PAADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 HSADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1051 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1134 MmADARI <	DrADAR1	KGDSLSLKGETVNDCHAEIISRRGFIRFLYNELMKYSPQTAKDSIFEPARGGEKLQIKKT	875
HsADARI KGDSLSLKGETVNDCHABIISRRGFIRFLYSELMKYNSGTAKDSIFEPAKGGEKLQIKKT 954 MmADARI KGDSLSLKGETVNDCHABIISRRGFIRFLYSELMKYNSGTAKDSIFEPAKGGEKLQIKKT 877 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 HsADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 HSADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKLLRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PAADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PAADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1051 HSADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1051 HSADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARDLKLSYGEAKKAARDVET 1115 HSADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1115 DrADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1114 HSADARI DLEILDGTRGTVDGPRELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1115 DrADARI DLEILDGTRGTVDGPRELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1115 PAADARI DLEILDGTRGTVDGPRELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1114 HSADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1226	PaADAR1	KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNPQTAKDSIFEPAKGGEKLQIKKT	871
MmaDAR1 KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNHHTAKNSIFELARGGEKLQIKKT 877 DrADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 935 PAADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 MmADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 931 DrADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 937 DrADAR1 VSFHLYISTAPCGDGALFDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 937 DrADAR1 SSDIVPTWDGIRLGERLRTMSCSDKLLRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PaADAR1 SSDIVPTWDGIRLGERLRTMSCSDKILLRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADAR1 SSDIVPTWDGIRLGERLRTMSCSDKILLRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADAR1 HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADG2 1055 PAADAR1 HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADG2 1051 HSADAR1 HLTRAICCRVTRDGSAFEDGLRPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADG2 1051 HSADAR1 HLTRAICCRVTRDGSAFEDGLRPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADG2 1051 PAADAR1 HLTRAICCRVTRDGSAFEDGLRPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADG2 1051 PAADAR1 HLTRAICCRVTRDGSAFEDGLRPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADG2 1	HsADAR1	KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNSQTAKDSIFEPAKGGEKLQIKKT	954
DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 935 PaADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDPRHYPVFENPKQGKLRTKVENGEGTIPVE 931 HsADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTDPRHYPVFENPKQGKLRTKVENGEGTIPVE 931 maDARI VSFHLYISTAPCGDGALFDKSCSDRAVESTESKHYPVFENPKQGKLRTKVENGEGTIPVE 931 DrADARI VSFHLYISTAPCGDGALFDKSCSDRAVESTESKHYPVFENPKQGKLRTKVENGEGTIPVE 937 Catalytic deaminase domain 937 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 PaADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 MmADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 PADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 PADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 PADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKROSGKTKETSVNWCLADGY 1055 PaADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKROSGKTKETSVNWCLADGY 1134 MmADARI HLTRAICCRVTRDGAFEDGLRUPFIVNHPKVGRVSVDSKROSGKTKETSVNWCLADGY 1134 MmADARI HLTRAICCRVTRDGAFEDGLRUPFIVNHPKVGRVSVDSKROSGKTKETSVNWCLADGY 1155 PAADARI	MmADAR1	KGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNHHTAKNSIFELARGGEKLQIKKT	877
DrADARI VSFHLYISTAPCGDCALPDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE 935 PAADARI VSFHLYISTAPCGDCALPDKSCSDRAVESTDPHRYPVFENPKQGKLRTKVENGEGTIPVE 931 HSADARI VSFHLYISTAPCGDCALPDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 931 OrADARI VSFHLYISTAPCGDCALPDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 937 Catalytic deaminase domain DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PAADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 DAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 DrADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1115 DFADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1116 HSADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1119 MMADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1110 DFADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1110 FAADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1110 FAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 HASADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1226			
PADARI VSFHLYISTAPCGDCALPDKSCSDRAVESTDPRRYPVENPKQGKLRTKVENGEGTIPVE 931 HSADARI VSFHLYISTAPCGDCALPDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 1014 MmADARI VSFHLYISTAPCGDGALPDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 937 catalytic deaminase domain DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PAADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 1074 HAADARI SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 1075 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1055 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1051 HSADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1051 DrADARI DLEILDGTRGTVDGPRNELSRVSKNIFLLFKRLCSFRARRDLLKLSYGEAKKAARDYET 1115 DrADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1119 MMADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1119 MMADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1119 DrADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1119 MMADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLLSYGEAKKAARDYET 1119 AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1226	DrADAR1	VSFHLYISTAPCGDGALFDKSCSDRAVESTDSRHYPVFENPKQGKLRTKVENGEGTIPVE	935
HsADARI VSFHLYISTAPCGDCALFDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 1014 MmADARI VSFHLYISTAPCGDCALFDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE 937 catalytic deaminase domain DrADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 BADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 HsADARI SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 1074 MmADAR1 SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPYYLKSVTLGYLFSQG 1074 MmADAR1 SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPYYLKSVTLGYLFSQG 1074 MmADAR1 SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPYYLKSVTLGYLFSQG 1074 MmADAR1 HLTRAICCRVTRDGSAFEDGLQPPFTVNHPKVGRVSYDSKRQSGKTKETSVNWCLADGY 1055 PaADAR1 HLTRAICCRVTRDGSAFEDGLRPPFIVNHPKVGRVSYDSKRQSGKTKETSVNWCLADGY 1057 PaADAR1 HLTRAICCRVTRDGSAFEDGLRYPFIVNHPKVGRVSYDSKRQSGKTKETSVNWCLADGY 1057 PaADAR1 DLEILDGTRGTVDGPRNELSRVSKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDYET 1115 PaADAR1 DLEILDGTRGTVDGPRESLSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDVET 1114 MmADAR1 DLEILDGTRGTVDGPKELSRVSKKNIFLQFKKLCSFRARRDLLLSYGEAKKAARDVET 1117 DF	PaADAR1	VSFHLYISTAPCGDGALFDKSCSDRAVESTDPRHYPVFENPKQGKLRTKVENGEGTIPVE	931
MmADAR1 VSFHLYISTAPCGDCALPDKSCSDRAVESTESKRYEVFENPKQGKLRKVENGEGTIPVE 937 catalytic deaminase domain 937 DrADAR1 SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PaADAR1 SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 MmADAR1 SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADAR1 HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 PaADAR1 HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1051 HSADAR1 HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1051 HSADAR1 HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1051 PaADAR1 HLTRAICCRVTRDGKAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1151 PaADAR1 DLEILDGTRGTVDGPRNELSRVSKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1111 HSADAR1 DLEILDGTRGTVDGPRSELSRVSKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1114 MmADAR1 DLEILDGTRGTVDGPRSELSRVSKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1117 MmADAR1 DLEILDGTRGTVDGPRSELSRVSKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1117 MMADAR1 DLEILDGTRGTVDGPRSELSRVSKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDVET 1117 MADAR1	HsADAR1	VSFHLYISTAPCGDGALFDKSCSDRAMESTESRHYPVFENPKQGKLRTKVENGEGTIPVE	1014
cctalytic deaminase domain DrADARI SSDIVPTWDGIRLGERLKTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 995 PaADARI SSDIVPTWDGIRLGERLKTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 991 HsADARI SSDIVPTWDGIRLGERLKTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI SSDIVPTWDGIRLGERLKTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADARI SSDIVPTWDGIRLGERLKTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 1055 PaADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1051 HaADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVDSKRQSGKTKETSVNWCLADGY 1051 PaADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSYDSKRQSGKTKETSVNWCLADGY 1134 MmADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSYDSKRQSGKTKETSVNWCLADGY 1115 PaADARI DLEILDGTRGTVDGPRNELSRVSKNIFLLFKKLCSFRARDLLKLSVGEAKKAARDVET 1115 PaADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRARDLLKLSVGEAKKAARDVET 1111 HSADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRRRDLLKLSVGEAKKAARDVET 1114 MmADARI DLEILDGTRGTVDGPGKELSRVSKKNIFLLFKKLCSFRRRDLLLSVGEAKKAARDVET 1117 C C C 1117 HMRADARI DLEILDGTRGTVDGPGWISKPQEEKNFYLCPV 1143	MmADAR1	VSFHLYISTAPCGDGALFDKSCSDRAVESTESRHYPVFENPKQGKLRTKVENGEGTIPVE	937
DrADARI SSDIVPTMOGIRLGERLRTMSCSDKILLRWNVLGLQGALLTHFLQPVYLKSVTLGVLFSQG 995 PAADARI SSDIVPTMOGIRLGERLRTMSCSDKILCRWNVLGLQGALLTHFLQPVYLKSVTLGVLFSQG 991 HSADARI SSDIVPTMOGIRLGERLRTMSCSDKILCRWNVLGLQGALLTHFLQPYVLKSVTLGVLFSQG 997 DrADARI HLTRAICCRVTRDGSAFEDGLQPPFTVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLQPPFTVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGC 1051 HSADARI HLTRAICCRVTRDGSAFEDGLQPPFTVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGC 1051 DrADARI HLTRAICCRVTRDGSAFEDGLQPPFTVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGC 1051 DrADARI HLTRAICCRVTRDGSAFEDGLQPPFTVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGC 1057 DrADARI DLEILDGTRGTVDGPRNELSRVSKNIFLLFKRLCSFRARRDLLKLSYGEAKKAARDVEA 1111 HSADARI DLEILDGTRGTVDGPRNELSRVSKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDVEA 1111 HSADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDVEA 1111 HSADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDVEA 1110 HSADARI DLEILDGTRGTVDGPRKELSRVSKKNIFLQFKKLCSFRGRRDLLRJSYGEAKKAARDVEA 1111 HSADARI DLEILDGTRGTVGPRKELSRVSKKNIFLQFKKLCSFRGRRDLLRJSYGEAKKAARDVEA 1110 HSADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 HSADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1226		catalytic deaminase domain	
PADARI SSDIVPTMOGIRLGERLRTMSCSDKILCMNVLGLQGALLTHFLQVVLKSVTLGVLFSQG 991 HSADARI SSDIVPTMOGIRLGERLRTMSCSDKILCMNVLGLQGALLTHFLQVVLKSVTLGVLFSQG 997 DrADARI BLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1051 HSADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1051 HSADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1131 HmADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKRLCSFRARDLKLSYGEAKKAARDYET 1115 PAADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1114 HSADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1194 MmADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1194 DrADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1194 MmADARI DLEILDGTRGTVDGPKELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1194 AMMADARI DLEILDGTRGTVDGPKELSRVSKKNIFLLFKKLCSFRGRDLLRJSGEAKKAARDYET 1194 AMMADARI DLEILDGTRGTVGGPKELSRVSKKNIFLLFKKLCSFRGRDLLRJSGEAKKAARDYET 1194 AMMADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1226	DrADAR1	SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG	995
HsADARI SSDIVPTWDGIRLGERLETMSCSDKILRWNVLGLQGALLTHFLQPTYLKSVTLGYLFSQG 1074 MmADARI SSDIVPTWDGIRLGERLETMSCSDKILRWNVLGLQGALLTHFLQPTYLKSVTLGYLFSQG 997 DrADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 PaADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1051 HADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSYDSKRQSGKTKETSVNWCLADGY 1134 MmADARI HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSYDSKRQSGKTKETSVNWCLADGY 1135 DrADARI DLEILDGTRGTVDGPRNELSRVSKNIFLLFKRLCSFRARRDLLKLSYGEAKKAARDYET 1115 PaADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1114 HsADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARDLLKLSYGEAKKAARDYET 1117 DrADARI DLEILDGTRGTVDGPGRELSRVSKKNIFLOFKKLCSFRARDLLRLSYGEAKKAARDYET 1119 MmADARI DLEILDGTRGTVDGPGRELSRVSKKNIFLOFKKLCSFRARDLLLSYGEAKKAARDYET 1117 DrADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 HASADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 HASADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1226	PaADAR1	SSDIVPTWDGIRLGERLRTMSCSDKILCWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG	991
MmaDAR1 SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG 997 DrADAR1 HLTRAICCRVTRDGSAFEDGLQPPFTVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 PaADAR1 HLTRAICCRVTRDGSAFEDGLQPPFTVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGC 1051 HSADAR1 HLTRAICCRVTRDGSAFEDGLQPPFTVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGC 1051 DrADAR1 HLTRAICCRVTRDGSAFEDGLQPPFTVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGC 1051 DrADAR1 DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKRLCSFRARRDLLKLSYGEAKKAARDYET 1115 PaADAR1 DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDYET 1111 HSADAR1 DLEILDGTRGTVDGPRKELSRVSKKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDYET 1114 MmADAR1 DLEILDGTRGTVDGPKKLSRVSKKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDYET 1117 DrADAR1 DLEILDGTRGTVDGPKKLSRVSKKNIFLLFKKLCSFRARRDLLLSYGEAKKAARDYET 1117 DrADAR1 AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PaADAR1 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 HASADAR1 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1126	HsADAR1	SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPIYLKSVTLGYLFSQG	1074
Dradari HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1055 Paadari HLTRAICCRVTRDGSAFEDGLQPPFTVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1051 Hsadari HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1131 Mmadari HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY 1131 Dradari HLTRAICCRVTRDGKAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCMADGY 1105 Dradari DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKRLCSFRARDLLKLSYGEAKKAARDYET 1111 HsADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1111 HsADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1194 MmADARI DLEILDGTRGTVDGPRKELSRVSKKNIFLQFKKLCSFRARDLLQLSYGEAKKAARDYET 1194 MmADARI DLEILDGTRGTVDGPKELSRVSKKNIFLQFKKLCSFRARDLLQLSYGEAKKAARDYET 1194 MmADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PaADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 HASADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1126	MmADAR1	SSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQGALLTHFLQPVYLKSVTLGYLFSQG	997
DFADARI HITKAICCKVIRDSAFEDGLRHFIVNHEKVGRVSVIDSKRQSGKTKETSVNWCLADGY 1055 PAADARI HITKAICCKVIRDSAFEDGLRPFIVNHEKVGRVSVIDSKRQSGKTKETSVNWCLADGY 1051 HsADARI HITKAICCRVIRDGSAFEDGLRPFIVNHEKVGRVSVIDSKRQSGKTKETSVNWCLADGY 1134 HITKAICCRVIRDGSAFEDGLRPFIVNHEKVGRVSVIDSKRQSGKTKETSVNWCLADGY 1135 DIADARI DLEILDGTRGTVDGPRNELSRVSKNIFLLFKRLCSFRARRDLLKLSYGEAKKAARDYET 1115 PAADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYET 1114 HSADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLRLSYGEAKKAARDYET 1194 MmADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLRLSYGEAKKAARDYET 1194 DIADARI AKNYFKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 HSADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1226	D 10101		1055
PAADARI HITKAICCKVIRDSAFEDGLØPFTVNHEKVGRVSVIDSKRQSGKTKETSVNMCLADGE 1051 HASADARI HITKAICCRVIRDSAFEDGLRPFTVNHEKVGRVSVDSKRQSGKTKETSVNMCLADGE 1134 MmADARI HITRAICCRVIRDSAFEDGLRYPFIVNHEKVGRVSVDSKRQSGKTKETSVNMCLADGE 1131 DrADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDYET 1115 PaADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYEA 1111 HSADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYEA 1111 MmADARI DLEILDGTRGTVDGPRKELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYEA 1111 DrADARI ALEILDGTRGTVDGPRKELSRVSKKNIFLLFKKLCSFRARRDLLRJSYGEAKKAARDYEA 1111 PaADARI DLEILDGTRGTVDGPRKELSRVSKKNIFLLFKKLCSFRARRDLLRJSYGEAKKAARDYEA 1111 PaADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PaADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 HASDARI AKNYFKKGLKOMGYGNWISKPQEEKNFYLCPV 1226	Dradari Dradari	HLTRAICCRVTRDGSAFEDGLRHPFIVNHPKVGRVSVYDSKRQSGKTKETSVNWCLADGY	1055
HADARI HITKAICCRVIRDSAEEDGLRHFTIVNERVGRVSIIDSARGSGKTKEISYNMCLADGI 1134 MmADARI HITKAICCRVIRDSAEEDGLRHFTIVNERVGRVSVIDSKRGSGKTKEISYNMCLADGI 1135 DrADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDYET 1115 PAADARI DLEILDGTRGTVDGPRELSRVSKKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDYET 1194 MmADARI DLEILDGTRGTVDGPRELSRVSKKNIFLLFKKLCSFRGRRDLLRJSYGEAKKAARDYET 1194 DLEILDGTRGTVDGPRELSRVSKKNIFLLFKKLCSFRARRDLLQLSYGEAKKAARDYET 1194 DLEILDGTRGTVDGPRELSRVSKKNIFLLFKKLCSFRARRDLLQLSYGEAKKAARDYET 1194 DLADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 HAADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1126	PAADARI	HLTRAICCRVTRDGSAFEDGLQPPFTVNHPRVGRVSVIDSRRQSGRTRETSVNWCLADGC	1124
MMADARI HITKAICCRVIRDGRAEEDGLKIFFIVNHERVORVSVIDSKRUSGRTRETSVNMCMADGY 1057 DrADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKRLCSFRARRDLLKLSYGEAKKAARDYET 1115 PAADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDYEA 1111 HSADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRARRDLLKLSYGEAKKAARDYEA 1111 MMADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRARRDLLLSYGEAKKAARDYEA 1117 DrADARI ALKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PaADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 HASADARI AKNYFKKGLKOMGYGNWISKPQEEKNFYLCPV 126	HSADARI	HLTRATCCRVTRDGSAFEDGLRHPFTVNHPKVGRVSTTDSKRQSGKTKETSVNWCLADGT	1057
DrADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKRLCSFRARRDLLKLSYGEAKKAARDYET 1115 PAADARI DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRGRDLLKLSYGEAKKAARDYEA 1111 HSADARI DLEILDGTRGTVDGPRBELSRVSKKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDYEA 1119 MmADARI DLEILDGTRGTVDGPRBELSRVSKKNIFLGFKKLCSFRARRDLLQLSYGEAKKAARDYEI 1194 MmADARI DLEILDGTRGTVDGPRBELSRVSKKNIFLGFKKLCSFRARRDLLQLSYGEAKKAARDYEI 1194 MMADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 HSADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1226	MMADARI	HLTRAICCRVTRDGRAFEDGLRIPFIVNHPRVGRVSVIDSRRQSGRTRETSVNWCMADGI	1057
DADARI DLEILDGTRGTVDGPRELSRVSKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDVEN 1111 HsADARI DLEILDGTRGTVDGPRELSRVSKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDVEN 1114 MmADARI DLEILDGTRGTVDGPRELSRVSKKNIFLLFKKLCSFRGRRDLLRJSYGEAKKAARDVEN 1194 MmADARI DLEILDGTRGTVDGPRELSRVSKKNIFLQFKKLCSFRARRDLLQLSYGEAKKAARDVEN 1194 MmADARI DLEILDGTRGTVDGPRELSRVSKKNIFLQFKKLCSFRARRDLLQLSYGEAKKAARDVEN 1194 MmADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1143 HsADARI AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 11226	Dradar1	DIFTI DOTDOTUDO DONEL SDUSKKNI FILEKDI OSEDADDDI I KI SVOFAKKAADDVET	1115
HSADARI DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRYRRDLLRLSYGEAKKAARDYET 1194 MmADARI DLEILDGTRGTVDGPGRELSRVSKKNIFLOFKKLCSFRARRDLLQLSYGEAKKAARDYET 1194 CADARI AKNYFKKSLKDMGYGNWISKPOEEKNFYLCPV 1147 PAADARI AKNYFKKSLKDMGYGNWISKPOEEKNFYLCPV 1143 HSADARI AKNYFKKSLKDMGYGNWISKPOEEKNFYLCPV 1226	PaADAR1	DLEILDGTRGTVDGPRSELSRVSKKNIFLLFKKLCSFRGRRDLLKLSYGEAKKAARDYEA	1111
MMADARI DLEILDGTRGTVDGPGRELSRVSKKNIFLGFKKLCSFRARDLLQLSYGEAKKAARDYDL 1117 MADARI AKNYFKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 HAADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1226	Headar1	DLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSFRYRRDLLRLSYGEAKKAARDYET	1194
DrADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 HAADARI AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1226	MmanaR1	DLETLDGTRGTVDGPGKELSRVSKKNIFLOFKKLCSFRARRDIJOLSVGFAKKAARDVDL	1117
DrADAR1 AKNYFKKSLKDMGYGNWISKPQEEKNFYLCPV 1147 PAADAR1 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 HSADAR1 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1226	FINISDATCE		111,
PAADAR1 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1143 HSADAR1 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1226	DrADAR1	AKNYFKKSLKDMGYGNWISKPOEEKNFYLCPV 1147	
HSADAR1 AKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV 1226	PaADAR1	AKNYFKKGLKDMGYGNWISKPOEEKNFYLCPV 1143	
	HsADAR1	AKNYFKKGLKDMGYGNWISKPOEEKNFYLCPV 1226	
MmADAR1 AKNYFKKSLRDMGYGNWISKPQEEKNFYLCPV 1149	MmADAR1	AKNYFKKSLRDMGYGNWISKPQEEKNFYLCPV 1149	









Figure 4.

